According to a study by Brader et al. (n.d.), an estimated number of 7–10 million Americans show early signs of developing age-related macular degeneration and are at significant risk of progression of AMD to advanced levels and Geographic Atrophy. In over a 15 year-time period, incidence of progression from early AMD to GA is estimated to be 14%.
The Geographic atrophy market size is anticipated to increase during the study period 2017–2030 owing to increasing Geographic atrophy prevalence, better understanding of disease pathophysiology, better therapies and pipeline candidates aimed at addressing the disease from its root.
The key companies in the Geographic Atrophy Market includes Apellis Pharmaceuticals, Alkeus Pharmaceuticals, Regenerative Patch Technologies, Ionis Pharmaceuticals, IVERIC bio (Opthotech), Alimera Sciences, Genentech, Gyroscope Therapeutics and others
For more details visit: https://www.delveinsight.com/blog/geographic-atrophy-market-size/